Kodiak Sciences (KOD) Stock Forecast, Price Target & Predictions
KOD Stock Forecast
Kodiak Sciences stock forecast is as follows: an average price target of $11.00 (represents a 26.66% upside from KOD’s last price of $8.69) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
KOD Price Target
KOD Analyst Ratings
Buy
Kodiak Sciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 09, 2024 | Michael Yee | Jefferies | $20.00 | $11.48 | 74.22% | 130.28% |
Sep 24, 2024 | Andrea Tan | Goldman Sachs | $2.00 | $2.43 | -17.78% | -76.97% |
Nov 14, 2022 | Morgan Stanley | $9.00 | $7.59 | 18.58% | 3.63% | |
Nov 10, 2022 | Goldman Sachs | $8.00 | $7.22 | 10.80% | -7.89% | |
Aug 15, 2022 | Morgan Stanley | $12.00 | $11.73 | 2.30% | 38.17% | |
Aug 10, 2022 | Chardan Capital | $18.00 | $11.84 | 52.03% | 107.25% | |
Aug 09, 2022 | Truist Financial | $15.00 | $11.13 | 34.77% | 72.71% | |
Aug 09, 2022 | Goldman Sachs | $9.00 | $11.55 | -22.08% | 3.63% | |
May 24, 2022 | Goldman Sachs | $5.00 | $6.55 | -23.66% | -42.43% | |
May 11, 2022 | Goldman Sachs | $7.00 | $5.20 | 34.62% | -19.40% | |
Feb 11, 2022 | Andrea Tan | Goldman Sachs | $70.00 | $56.79 | 23.26% | 705.99% |
Nov 12, 2021 | Matthew Luchini | BMO Capital | $114.00 | $112.33 | 1.49% | 1212.61% |
Kodiak Sciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 2 |
Avg Price Target | $20.00 | $11.00 | $11.00 |
Last Closing Price | $8.69 | $8.69 | $8.69 |
Upside/Downside | 130.28% | 26.66% | 26.66% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 24, 2024 | Goldman Sachs | Sell | Sell | Hold |
Sep 05, 2024 | H.C. Wainwright | Neutral | Initialise | |
Apr 04, 2024 | UBS | Neutral | Neutral | Hold |
Apr 01, 2024 | Barclays | Underweight | Underweight | Hold |
Jul 24, 2023 | Raymond James | Outperform | Initialise | |
Jul 24, 2023 | Citigroup | Neutral | Overweight | Initialise |
Jul 24, 2023 | RBC Capital | Outperform | Initialise | |
Jul 24, 2023 | Barclays | Equal-Weight | Initialise | |
Jul 24, 2023 | Goldman Sachs | Neutral | Buy | Initialise |
Nov 14, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Aug 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Aug 10, 2022 | Chardan Capital | Buy | Buy | Hold |
Aug 09, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
May 17, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
May 11, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
Feb 24, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Feb 24, 2022 | Citigroup | Neutral | Neutral | Hold |
Kodiak Sciences Financial Forecast
Kodiak Sciences Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $408.04K | $10.57K |
High Forecast | - | - | - | - | - | - | - | $489.64K | $12.68K |
Low Forecast | - | - | - | - | - | - | - | $326.43K | $8.46K |
# Analysts | - | - | - | - | - | - | - | 16 | 14 |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kodiak Sciences EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 16 | 14 |
EBITDA | - | - | - | - | - | - | - | $-24.17M | $-7.85M |
Avg Forecast | - | - | - | - | - | - | - | $-21.07M | $-10.74M |
High Forecast | - | - | - | - | - | - | - | $-16.86M | $-8.59M |
Low Forecast | - | - | - | - | - | - | - | $-25.28M | $-12.89M |
Surprise % | - | - | - | - | - | - | - | 1.15% | 0.73% |
Forecast
Kodiak Sciences Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 16 | 14 |
Net Income | - | - | - | - | - | - | - | $-24.39M | $-7.98M |
Avg Forecast | $-49.99M | $-58.14M | $-61.03M | $-55.25M | $-46.48M | $-47.60M | $-45.80M | $-20.15M | $-10.29M |
High Forecast | $-49.99M | $-58.14M | $-61.03M | $-51.20M | $-41.67M | $-47.60M | $-45.80M | $-16.12M | $-8.23M |
Low Forecast | $-49.99M | $-58.14M | $-61.03M | $-59.29M | $-51.29M | $-47.60M | $-45.80M | $-24.18M | $-12.35M |
Surprise % | - | - | - | - | - | - | - | 1.21% | 0.78% |
Forecast
Kodiak Sciences SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 16 | 14 |
SG&A | - | - | - | - | - | - | - | $5.55M | $2.74M |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kodiak Sciences EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 16 | 14 |
EPS | - | - | - | - | - | - | - | $-0.54 | $-0.21 |
Avg Forecast | $-0.95 | $-1.10 | $-1.16 | $-1.05 | $-0.88 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
High Forecast | $-0.95 | $-1.10 | $-1.16 | $-0.97 | $-0.79 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
Low Forecast | $-0.95 | $-1.10 | $-1.16 | $-1.13 | $-0.97 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
Surprise % | - | - | - | - | - | - | - | 1.16% | 0.57% |
Forecast
Kodiak Sciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
CKPT | Checkpoint Therapeutics | $3.72 | $20.00 | 437.63% | Buy |
BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
KOD | Kodiak Sciences | $8.87 | $11.00 | 24.01% | Buy |
MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |